5-Nitroindole

We are 5-Nitroindole CAS:6146-52-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:5-Nitroindole
CAS.NO:6146-52-7
Synonyms:5-Nitroindole
5-nitro-indole
5-Nitroindolyl radical
5-nitro-indol
5-nitrolindole
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 362.6±15.0 °C at 760 mmHg
Melting Point 140-142 °C(lit.)
Molecular Formula C8H6N2O2
Molecular Weight 162.145
Flash Point 173.1±20.4 °C
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.723
 
Specification:
Appearance:Orange solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Zafirlukast(CAS:107753-78-6).

5-Nitroindole


Related News: “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.Ácido 3-hidroxifenilborónico CAS:87199-18-6 Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.99-15-0 Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.80-58-0 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
4-Cyanophenylboronic acid View Details
(R)-(-)-4-Phenyl-2-Oxazolidinone View Details
(S)-4-Methyloxazolidine-2,5-dione View Details
methyl-bis[[methyl(diphenyl)silyl]oxy]-phenylsilane manufacturer 3-bromo-1,2-difluoro-4-nitrobenzene manufacturer 3-Fluoropicolinic acid manufacturer 3-Diethylaminophenol manufacturer 2,3-Dichloroquinoxaline manufacturer